Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Tuesday, January 27, 2015

Missouri to save $4.2 million by switching hepatitis C drug

JEFFERSON CITY, Mo. (AP) — State officials say Missouri’s Medicaid program will save an estimated $4.2 million in fiscal year 2016 by using a newer, cheaper drug to treat hepatitis C.

The state joined a group of 25 other states to receive rebates on Viekira from drug maker AbbVie. The state in most cases will provide that drug instead of Gilead Science’s Sovaldi in an agreement announced Monday.

The expensive treatment with Sovaldi, about $84,000 for a normal course, was cited as one driver of increased Medicaid costs for the state in 2015 by the state budget director.

Read more...
Posted by at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)